Revenue amounted to 138.8 MSEK (127.9), an increase of 8.5 percent, of which a negative organic growth of 1.9 percent. The quarter was negatively impacted by the phase-out of non-strategic products in surgical instruments that began in early 2025 and a negative currency effect. Adjusted for these two factors, underlying organic growth would have amounted to 7.3 percent.
“We had a continued strong demand and acquisition-driven sales growth in a quarter characterized by negative currency effects and stabilization of the supply chain” says Ulrik Berthelsen. “Looking ahead to 2026, we anticipate a return to growth driven by a combination of strong order intake, operational improvements and commercial execution.”
The gross profit margin in the quarter amounted to 48.8 percent (53.1) and EBIT before non-recurring items amounted to 17.3 MSEK (24.4).
| MSEK | JUL–SEP 2025 | JUL–SEP 2024 | JAN–SEP 2025 | JAN–SEP 2024 | OCT–SEP 2024/2025 | JAN–DEC 2024 |
| Net sales | 138.8 | 127.9 | 392.7 | 408.7 | 554.0 | 569.9 |
| Gross profit, % | 48.8 | 53.1 | 50.6 | 49.3 | 52.1 | 51.9 |
| EBITDA before non-recurring items | 26.1 | 31.3 | 75.7 | 96.2 | 122.0 | 142.4 |
| EBITDA before non-recurring items, % | 18.8 | 24.5 | 19.3 | 23.5 | 22.0 | 25.0 |
| EBITDA | 19.0 | 31.3 | 68.6 | 76.1 | 90.5 | 98.0 |
| EBITDA, % | 13.7 | 24.5 | 17.5 | 18.6 | 16.3 | 17.2 |
| EBIT before non-recurring items | 17.3 | 24.4 | 51.8 | 75.7 | 91.0 | 114.9 |
| EBIT before non-recurring items, % | 12.5 | 19.1 | 13.2 | 18.5 | 16.4 | 20.2 |
| EBIT | 10.3 | 24.4 | 44.7 | 55.7 | 59.5 | 70.5 |
| EBIT, % | 7.4 | 19.1 | 11.4 | 13.6 | 10.7 | 12.4 |